Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001415889-25-020462
Filing Date
2025-07-29
Accepted
2025-07-29 16:53:05
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 20137
2 JOINT FILING AGREEMENT ex-99-07292025_080758.htm EX-99.1 38462
  Complete submission text file 0001415889-25-020462.txt   60396
Mailing Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Atlas Venture Fund X, L.P. (Filed by) CIK: 0001628098 (see all company filings)

EIN.: 472435989 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 12526 HIGH BLUFF DRIVE SAN DIEGO CA 92130
Business Address 12526 HIGH BLUFF DRIVE SAN DIEGO CA 92130 857-343-8292
ImageneBio, Inc. (Subject) CIK: 0001835579 (see all company filings)

EIN.: 811697316 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92449 | Film No.: 251162457
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)